Table 2 Resource consumption
From: Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain
HTP | LITP | ||||||
|---|---|---|---|---|---|---|---|
Resource | MAW | Methadone 1 st year | Methadone 2 nd & 3 rd year | B/N 1 st year | B/N 2 nd & 3 rd year | Methadone | B/N |
Distribution | 365 | 365 | |||||
Production | 365 | 365 | 365 | ||||
Dispensing | 36 | 104 | 52 | 52 | |||
Supervision | |||||||
drug-pharmacy | 36 | 365 | 365 | 365 | |||
medical/clinical | 6 | 6 | |||||
psychological | 20 | 20 | 10 | 20 | 5 | ||
social worker | 15 | 10 | 10 | 10 | 5 | 6 | 6 |
psychiatric | 10 | 10 | 10 | 10 | 5 | ||
Monitoring (analytical controls) | 36 | 12 | 12 | 12 |